The 2011 Canadian cardiovascular society heart failure management guidelines update: Focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care

Canadian Journal of Cardiology

Volumn 27, Issue 3, 2011, Pages 319-338

  McKelvie, Robert S ^a   Moe, Gordon W ^b   Cheung, Anson ^c   Costigan, Jeannine ^d   Ducharme, Anique ^e   Estrella Holder, Estrellita ^f   Ezekowitz, Justin A ^g   Floras, John ^h   Giannetti, Nadia ⁱ   Grzeslo, Adam ^a,j   Harkness, Karen ^a   Heckman, George A ^a,k   Howlett, Jonathan G ^l   Kouz, Simon ^m   Leblanc, Kori ^h   Mann, Elizabeth ⁿ   O'Meara, Eileen ^e   Rajda, Miroslav ^o   Rao, Vivek ^h   Simon, Jessica ^l   Swiggum, Elizabeth ^p   Zieroth, Shelley ^f   Arnold, J Malcolm O ^q   Ashton, Tom ^r   D'Astous, Michel ^s   Dorian, Paul ^h   Haddad, Haissam ^t   Isaac, Debra L ^l   Leblanc, Marie Hélène ^u   Liu, Peter ^h   Sussex, Bruce ^v   Ross, Heather J ^h   more..

^a MCMASTER UNIVERSITY   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d St Mary's General Hospital   (Canada)

^e MONTREAL HEART INSTITUTE   (Canada)

^f ST BONIFACE GENERAL HOSPITAL   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ MCGILL UNIVERSITY   (Canada)

^j Joseph Brant Memorial Hospital Burlington   (Canada)

^k UNIVERSITY OF WATERLOO   (Canada)

^l UNIVERSITY OF CALGARY   (Canada)

^m UNIVERSITÉ LAVAL   (Canada)

ⁿ DALHOUSIE UNIVERSITY   (Canada)

^o QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^p ROYAL JUBILEE HOSPITAL   (Canada)

^q UNIVERSITY OF WESTERN ONTARIO   (Canada)

^r Western Ontario ^*

^s UNIVERSITÉ DE MONCTON   (Canada)

^t UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^u LAVAL UNIVERSITY   (Canada)

^v Health Sciences Centre St John's   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD VESSEL INJURY; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR EQUIPMENT; DISEASE ASSOCIATION; DISEASE SEVERITY; HEALTH CARE QUALITY; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MECHANICAL CIRCULATORY SUPPORT; MEDICAL LITERATURE; ORGAN DONOR; PALLIATIVE THERAPY; PATIENT ASSESSMENT; PATIENT CARE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; SLEEP APNEA SYNDROME; SURVIVAL; TERMINAL CARE; THROMBOEMBOLISM; TREATMENT PLANNING;

EID: 79960831092     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2011.03.011     Document Type: Article

References (295)

1. Arnold JMO, Liu P, Demers C, et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006;22:23-45.
2. Arnold JMO, Howlett JG, Dorian P, et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol 2007;23:21-45.
3. Arnold JMO, Howlett JG, Ducharme A, et al. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure-2008 update: Best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. Can J Cardiol 2008;24:21-40.
4. Howlett JG, McKelvie RS, Arnold JMO, et al. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. Can J Cardiol 2009;25:85-105.
5. Howlett JG, McKelvie RS, Costigan J, et al. The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. Can J Cardiol 2010;26:185-202.
6. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336: 924-926.
7. St John Sutton MG, Abraham WT, Smith AL, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 2003;107:1985-90.
8. Higgins SL,HummelJD, Niazi IK, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003;42: 1454-9.
9. AbrahamWT, Young JB, León AR, et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation 2004;110:2864-8.
10. Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008;52:1834-43.
11. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events.NEngl J Med 2009;361:1329-38.
12. Tang ASL, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure.NEngl J Med 2010;363:2385-95.
13. Al-Majed NS, McAlister FA, Bakal JA, et al. Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure. Ann Intern Med 2011;154:401-12.
14. Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 2009;53:286-290.
15. Ezekowitz JA, McAlisterFA.Aldosterone blockadeandleft ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009;30:469-77.
16. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms.NEngl J Med 2011;364:11-21.
17. Fox K,FordI, StegPG,et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet 2008;372:817-21.
18. DiazA, BourassaMG,GuertinMC,et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005;26:967-74.
19. Flannery G, Gehrig-Mills R, Billah B, et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers.AmJ Cardiol 2008;101:865-9.
20. McAlister FA, Wiebe N, Ezekowitz JA, et al. Meta-analysis: ß-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009;150:784-94.
21. KomajdaM, Follath F, Swedberg K, et al. The EuroHeart Failure survey programme- a survey on the quality of care among patients with heart failure in Europe, Part 2: treatment. Eur Heart J 2003;24:464-74.
22. Komajda M, Hanon O, Hochadel M, et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J 2009;30:478-86.
23. Savelieva I, Camm AJ. If inhibition with ivabradine electrophysiological effects and safety. Drug Saf 2008;31:95-107.
24. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet 2010; 376:875-85.
25. Fox K, Ford I, Steg G, et al; on behalf of the BEAUTIFUL Investigators. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL Trial. Eur Heart J 2009;30:2337-45.
26. Pfisterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009;301:383-92.
27. Lainchbury JG, TroughtonRW,StrangmanKM,et al. N-terminal pro b-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED(NT-pro-BNP Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) Trial. J Am Coll Cardiol 2010;55:53-60.
28. Eurlings LWM, van Pol PEJ, Kok WE, et al. Management of chronic heart failure guided by individual N-terminal pro B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) Study. J Am Coll Cardiol 2010;56:2090-100.
29. Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation 2010;121:2592-600.
30. Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010;31:703-11.
31. MullensW, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009;53:589-96.
32. DammanK, vanDeursenVM,NavisG,et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009;53:582-8.
33. Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006; 47:1987-96.
34. Harnett JD, Foley RN, Kent GM, et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995;47: 884-90.
35. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
36. K/DOQIclinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002;39:S1-246.
37. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure: definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-12.
38. Palevsky PM. Renal replacement therapy I: indications and timing. Crit Care Clin 2005;21:347-56.
39. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003;41:1438-44.
40. WinkelmayerWC, CharytanDM,Levin R, et al. Poor short-term survival and low use of cardiovascular medications in elderly dialysis patients after acute myocardial infarction. Am J Kidney Dis 2006;47:301-8.
41. Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinoprilandimplications for future studies. Kidney Int 2006;70:1318-24.
42. SuzukiH, Kanno Y, Sugahara S, et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 2008;52:501-6.
43. Cice G, Di BA, D'Isa S, et al. Effects of telmisartan added to Angiotensinconverting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol 2010;56:1701-8.
44. Hussain S, Dreyfus DE, Marcus RJ, et al. Is spironolactone safe for dialysis patients? Nephrol Dialysis Transpl 2003;18:2364-8.
45. Saudan P, Mach F, Perneger T, et al. Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dialysis Transpl 2003;18: 2359-63.
46. Evan G, Marcos R, Susan D, et al. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients [abstract]. Am J Kidney Dis 2005;46:94-101.
47. Taheri S, MortazaviM,Shahidi S, et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transpl 2009;20:392-7.
48. KnollG, Cockfield S, Blydt-Hansen T, et al. Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation.CMAJ2005; 173:S1-25.
49. Ferreira SR, Moises VA, Tavares A, et al. Cardiovascular effects of successful renal transplantation: a 1-year sequential study of left ventricular morphology and function, and 24-hour blood pressure profile. Transplantation 2002;74: 1580-7.
50. Wali RK,WangGS, Gottlieb SS, et al. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol 2005;45: 1051-60.
51. Parfrey PS, Harnett JD, Foley RN, et al. Impact of renal transplantation on uremic cardiomyopathy. Transplantation 1995;60:908-14.
52. Fonarow GC, Corday E. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail Rev 2004;9: 179-85.
53. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006;97:1759-64.
54. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004;147:331-8.
55. Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded PatientsWith Decompensated Congestive Heart Failure (RAPID-CHF) trial. JAmColl Cardiol 2005;46:2043-6.
56. CostanzoMR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675-83.
57. Kazory A, Ross EA. Contemporary trends in the pharmacological and extracorporealmanagementof heart failure: a nephrologic perspective. Circulation 2008; 117:975-83.
58. Bradley TD, Floras JF. Obstructive sleep apnoea and its cardiovascular consequences. Lancet 2009;373:82-93.
59. Bradley TD, Floras JS. Sleep apnea and heart failure: part I: obstructive sleep apnea. Circulation 2003;107:1671-8.
60. Shiota JS, RyanCM,Chiu KL, et al. Alterations in upper airway cross-sectional area in response to lower body positive pressure in healthy subjects. Thorax 2007;62:868-72.
61. YuminoD, Redolfi S, Ruttanaumpawan P, et al. Nocturnal rostral fluid shift: a unifying concept for the pathogenesis of obstructive and central sleep apnea in men with heart failure. Circulation 2010;1598-605.
62. Giannoni A,EmdinM,Poletti R, et al. Clinical significance of chemosensitivity in chronic heart failure: influence on neurohormonal derangement, Cheyne-Stokes respiration and arrhythmias. Clin Sci 2008;114:489-97.
63. Floras JS. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol 2009;54:375-85.
64. Bradley TD, Floras JS. Sleep apnea and heart failure: part II: central sleep apnea. Circulation 2003;107:1822-6.
65. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation scientific statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. Circulation 2008;118:1080-111.
66. Floras JS, BradleyTD.Treating obstructive sleep apnea: is theremoreto the story than 2 millimeters of mercury? Hypertension 2007;50:289-91.
67. YoungME. The circadian clock within the heart: potential influence on myocardial gene expression, metabolism, and function. Am J Physiol Heart Circ Physiol 2006;290:H1-H16.
68. GottliebDJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the Sleep Heart Health Study. Circulation 2010;352-60.
69. Lanfranchi PA, Braghiroli A, Bosimini E, et al. Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Circulation 1999;99:1435-40.
70. Sin DD, Logan AG, Fitzgerald FS, et al. Effects of continuous positive airway pressure on long-term outcomes in heart failure patients with and without Cheyne-Stokes respiration. Circulation 2000;102:61-6.
71. Wang H, Parker JD, Newton GE, et al. Influence of obstructive sleep apnea on mortality in patients with heart failure. J Am Coll Cardiol 2007;49:1625-31.
72. Javaheri S, Shukla R, Zeigler H, et al. Central sleep apnea, right ventricular dysfunction, and low diastolic blood pressure are predictors of mortality in systolic heart failure. J Am Coll Cardiol 2007;49:2028-34.
73. Sin D, Fitzgerald F, Parker JD, et al. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med 1999;160:1101-6.
74. Kaneko Y, Floras JS, Usui K, et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea.N Engl J Med 2003;348:1233-41.
75. ArztM,Young T, Finn L, et al. Sleepiness and sleep in patients with both systolic heart failure and obstructive sleep apnea. Arch Intern Med 2006;166:1716-22.
76. Bradley TD, Logan AG, Kimoff RJ, et al. Continuous positive airway pressure for central sleep apnea and heart failure.N Engl J Med 2005;353:2025-33.
77. Tkacova R, Niroumand M, Lorenzi-Filho G, et al. Overnight shift from obstructive to central apneas in patients with heart failure: role ofPCO2and circulatory delay. Circulation 2001;103:238-43.
78. Ryan CM, Floras JS, Logan AG, et al. Shift in sleep apnea type in heart failure patients in the CANPAP Trial. Eur Respir J 2010;592-7.
79. MacDonald M, Fang J, Pittman SD, et al. The current prevalence of sleep disordered breathing in congestive heart failure patients treated with beta-blockers. Clin Sleep Med 2008;4:38-42.
80. Bitter T, Westerheide N, Prinz C, et al. Cheyne-Stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-defibrillator therapies in patients with congestive heart failure. Eur Heart J 2011;32:61-74.
81. Sin DD,Fitzgerald F, Parker JD, et al. Relationship of systolic BP to obstructive sleep apnea in patients with heart failure. Chest 2003;123:1536-43.
82. Tkacova R, Rankin F, Fitzgerald FS, et al. Effects of continuous positive airway pressure on obstructive sleep apnea and left ventricular afterload in patients with heart failure. Circulation 1998;98:2269-75.
83. NakashimaH, Katayama T, Takagi C, et al. Obstructive sleep apnoea inhibits the recovery of left ventricular function in patients with acute myocardial infarction. Eur Heart J 2006;27:2317-22.
84. Usui K, Parker JD, Newton GE, et al. Left ventricular structural adaptations to obstructive sleep apnea in dilated cardiomyopathy. Am J Respir Crit Care Med 2006;173:1170-5.
85. Arias MA, Garcia-Rio F, Alonso-Fernandez A, et al. Obstructive sleep apnea syndrome affects left ventricular diastolic function: effects of nasal continuous positive airway pressure in men. Circulation 2005;112:375-83.
86. Kim SH, Cho GY, Shin C, et al. Impact of obstructive sleep apnea on left ventricular diastolic function. Am J Cardiol 2008;101:1663-8.
87. Oldenburg O, Lamp B, Faber L, et al. Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of prevalence in and characteristics of 700 patients. Eur J Heart Fail 2007;251-7.
88. Oldenberg O, Bitter T, Wiemer M, et al. Pulmonary capillary wedge pressure and pulmonary arterial pressure in heart failure patients with sleep-disordered breathing. Sleep Med 2009;10:726-30.
89. O'Meara E, Clayton T, McEntegart MB, et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007;115:3111-20.
90. Bitter T, Faber L, Hering D, et al. Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction. Eur J Heart Fail 2009;11:602-8.
91. The report of an American Academy of Sleep Medicine Task Force. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. Sleep 1999;22:667-89.
92. Redline S, Budhiraja R,KapurV, et al.Thescoring of respiratory events in sleep: reliability and validity. J Clin Sleep Med 2007;3:169-200.
93. Ryan CM, Bradley TD. Periodicity of obstructive sleep apnea in patients with and without heart failure. Chest 2005;127:536-42.
94. Floras JS. Should sleep apnoea be a specific target of therapy in chronic heart failure? Heart 2009;95:1041-6.
95. Usui K, Bradley TD, Spaak J, et al. Inhibition of awake sympathetic nerve activity of heart failure patients with obstructive sleep apnea by nocturnal continuous positive airway pressure. J Am Coll Card 2005;45:2008-11.
96. Ryan CM, Usui K, Floras JS, et al. Effect of continuous positive airway pressure on ventricular ectopy in heart failure patients with obstructive sleep apnoea. Thorax 2005;60:781-5.
97. Gilman MP, Floras JS, Usui K, et al. Continuous positive airway pressure increases heart rate variability in heart failure patients with obstructive sleep apnoea. Clin Sci 2008;114:243-9.
98. Ruttanaumpawan P, GilmanMP,Usui K, et al. Sustained effect of continuous positive airway pressure on baroreflex sensitivity in congestive heart failure patients with obstructive sleep apnea. J Hypertens 2008;26:1163-8.
99. Mansfield D, Gollogly NC, Kaye DM, et al. Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure.AmJ Respir Crit Care Med 2004;169:361-6.
100. Smith LA, Vennelle M, Gardner RS, et al. Auto-titrating continuous positive airway pressure therapy in patients with chronic heart failure and obstructive sleep apnoea: a randomized placebo-controlled trial. Eur Heart J 2007;28: 1221-7.
101. Yoshinaga K, Burwash IG, Leech JA, et al. The effects of continuous positive airway pressure on myocardial energetics in patients with heart failure and obstructive sleep apnea. J Am Coll Cardiol 2007;49:450-8.
102. Naughton MT, Liu PP, Bernard DC, et al. Treatment of congestive heart failureandCheyne-Stokes respiration during sleep by continuous positive airway pressure. Am J Respir Crit Care Med 1995;151:92-7.
103. Tkacova R, Liu PP, Naughton MT, et al. Effect of continuous positive airway pressure on mitral regurgitant fraction and atrial natriuretic peptide in patients with heart failure. J Am Coll Cardiol 1997;30:739-45.
104. NaughtonMT,BenardDC,Liu PP, et al. Effects of nasalCPAPonsympathetic activity in patients with heart failure and central sleep apnea. Am J Respir Crit Care Med 1995;152:473-9.
105. ArztM, Floras JS, Logan AG, et al. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: a post hoc analysis of the Canadian Positive Airway Pressure for Patients with Central SleepApneaandHeart Failure Trial(CANPAP).Circulation 2007;115: 3173-80.
106. ArztM, Wensel R, Montalvan S, et al. Effects of dynamic bilevel positive airway pressure support on central sleep apnea in men with heart failure. Chest 2008; 134:61-6.
107. Kasai T, Usui Y, Yoshioka T, et al. Effect of flow-triggered adaptive servoventilation compared with continuous positive airway pressure in patients with chronic heart failure with coexisting obstructive sleep apnea and Cheyne-Stokes respiration. Circ Heart Fail 2010;3:140-8.
108. Gotsopoulos H, Kelly JJ, Cistulli PA. Oral appliance therapy reduces blood pressure in obstructive sleep apnea: a randomized, controlled trial. Sleep 2004; 27:934-41.
109. BarnesM, McEvoy RD, Banks S, et al. Efficacy of positive airway pressure and oral appliance inmildtomoderateobstructive sleep apnea.AmJ Respir CritCare Med 2004;170:656-64.
110. Mak S, Azevedo E, Liu P, et al. Effect of hyperoxia on left ventricular function and filling pressures in patients with and without congestive heart failure. Chest 2001;120:467-73.
111. Staniforth AD, Kinnear WJM, Starling R, et al. Effect of oxygen on sleep quality, cognitive function and sympathetic activity in patients with chronic heart failure and Cheyne-Stokes respiration. Eur Heart J 1998;19:922-8.
112. Szollosi I, Jones M, Morrell MJ, et al. Effect of CO2 inhalation on central sleep apnea and arousals from sleep. Respiration 2004;71:493-8.
113. Pepin JL, Defaye P, Garrigue S, et al. Overdrive atrial pacing does not improve obstructive sleep apnea syndrome. Eur Respir J 2005;25:343-7.
114. Floras JS, Bradley TD. Atrial overdrive pacing for sleep apnea; a door now closed? Am J Respir Crit Care Med 2005;172:118-22.
115. Manistry CH, Willson K, Davies JE, et al. Induction of oscillatory ventilation pattern using dynamic modulation of heart rate through a pacemaker. Am J Physiol 2008;295:R219-27.
116. Coventry PA, GrandeGE,RichardsDA,et al. Prediction of appropriate timing of palliative care for older adults with non-malignant life-threatening disease: a systematic review. Age Ageing 2005;34:218-27.
117. Howlett J, Morin L, Fortin M, et al. End-of-life planning in heart failure: it should be the end of the beginning. Can J Cardiol 2010;26:135-41.
118. AndersonH,WardC, Eardley A, et al.Theconcerns of patients under palliative care and a heart failure clinic are not being met. Palliat Med 2001;15:279-86.
119. Boyd KJ, Murray SA, Kendall M, et al. Living with advanced heart failure: a prospective, community based study of patients and their carers. Eur J Heart Fail 2004;6:585-91.
120. Solano JP, Gomes B, Higginson IJ.A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symp Manage 2006;31:58-69.
121. O'Leary N, Murphy NF, O'Loughlin C, et al. A comparative study of the palliative care needs of heart failure and cancer patients. Eur J Heart Fail 2009; 11:406-12.
122. Nordgren L, Sörensen S. Symptoms experienced in the last six months of life in patients with end-stage heart failure. Eur J Cardiovasc Nurs 2003;2:213-7.
123. GottM, Barnes S, Parker C, et al. Dying trajectories in heart failure. PalliatMed 2007;21:95-9.
124. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model.JAMA 2003;290:2581-7.
125. LevyWC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006;113:1424-33.
126. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997;95:2660-7.
127. Moss AH, Lunney JR, Culp S, et al. Prognostic significance of the "surprise" question in cancer patients. J Palliat Med 2010;13:837-40.
128. MossAH, GanjooJ,SharmaS, et al. Utility of the "surprise" question to identify dialysis patients with high mortality. Clin J Am Soc Nephrol 2008;3:1379-84.
129. Head B, Ritchie CS, Smoot TM. Prognostication in hospice care: can the palliative performance scale help? J Palliat Med 2005;8:492-502.
130. Harrold J, Rickerson E, Carroll JT, et al. Is the palliative performance scale a useful predictor of mortality in a heterogeneous hospice population? J Palliat Med 2005;8:503-9.
131. BrezinskiD, Stone PH, Muller JE, et al. Prognostic significance of the Karnofsky Performance Status score in patients with acute myocardial infarction: comparison with the left ventricular ejection fraction and the exercise treadmill test performance. The MILIS Study Group. Am Heart J 1991;121:1374-81.
132. Hupcey JE, Penrod J, Fenstermacher K. A model of palliative care for heart failure. Am J Hosp Palliat Care 2009;26:399-404.
133. ThompsonKA, Bharadwaj P, Philip KJ, et al. Heart failure therapy: beyond the guidelines. J Cardiovasc Med 2010;11:919-27.
134. Sudore RL, Fried TR. Redefining the "planning" in advance care planning: preparing for end-of-life decision making. Ann Intern Med 2010 17;153:256-61.
135. Davidson PM. Difficult conversations and chronic heart failure: do you talk the talk or walk the walk? Curr Opin Support Palliat Care 2007;1: 274-8.
136. Harding R, Selman L, Beynon T, et al. Meeting the communication and information needs of chronic heart failure patients. J Pain Symptom Manage 2008;36:149-56.
137. Heyland DK. Tranmer J, Feldman-Stewart D. End-of-life decision making in the seriously ill hospitalized patient: an organizing framework and results of a preliminary study. J Palliat Care 2000;16:S31-9.
138. Laakkonen M-L, Pitkala KH, Strandberg TE, et al. Older people's reasoning for resuscitation preferences and their role in the decision-making process. Resuscitation 2005;65:165-71.
139. Caldwell PH, Arthur HM, Demers C. Preferences of patients with heart failure for prognosis communication. Can J Cardiol 2007;23:791-6.
140. Formiga F, Chivite D, Ortega C, et al. End-of-life preferences in elderly patients admitted for heart failure. QJM 2004;97:803-8.
141. Hauptman PJ, Havranek EP. Integrating palliative care into heart failure care. Arch Intern Med 2005;165:374-8.
142. Frank C, Heyland DK, Chen B, et al. Determining resuscitation preferences of elderly inpatients: a review of the literature. CMAJ 2003;169: 795-9.
143. Heyland DK, Dodek P, Rocker G, et al. Canadian Researchers End-of-Life Network (CARENET). What matters most in end-of-life care: perceptions of seriously ill patients and their family members. CMAJ 2006; 174:627-33.
144. Buckman R. Communication skills in palliative care: a practical guide. Neurol Clin 2001;19:989-1004.
145. Clayton JM, Hancock KM, Butow PN, et al. Clinical practice guidelines for communicating prognosis and end-of-life issues with adults in the advanced stages of a life-limiting illness, and their caregivers. Med J Aust 2007;186:S77-108.
146. Buckman R. Words that make a difference: enhancing the "How" in "How we say it." Support Cancer Ther 2006;3:127.
147. Pantilat SZ. Communicating with seriously ill patients: better words to say. JAMA 2009;301:1279-81.
148. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J 1992;124:1017-25.
149. Green CP, Porter CB, Bresnahan DR, et al. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000;35:1245-55.
150. Wiklund I, Lindvall K, Swedberg K, et al. Self-assessment of quality of life in severe heart failure. Scand J Psychol 1987;28:220-5.
151. Guyatt GH, Nogradi S, Halcrow S, et al. Development and testing of a new measure of health status for clinical trials in heart failure. Gen Intern Med 1989;4:101-7.
152. O'Leary CJ, Jones PW. The left ventricular dysfunction questionnaire (LVD-36): reliability, validity, and responsiveness. Heart 2000; 83:634-40.
153. Zambroski CH, Lennie T, Chung ML, et al. Use of the Memorial Symptom Assessment Scale-Heart Failure in heart failure patients. Circulation 2004;110(suppl III):17.
154. Bruera E, Kuehn N, Miller MJ, et al. The Edmonton Symptom Assessment System (ESAS): a simple method of the assessment of palliative care patients. Journal of Palliative Care 1991;7:69.
155. Garratt A, Schmidt L, Mackintosh A, et al. Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ 2002;324:1417.
156. Fadol A, Mendoza T, Gning I, et al. Psychometric testing of the MDASIHF: a symptom assessment instrument for patients with cancer and concurrent heart failure. J Card Fail 2008;14:497-507.
157. Glajchen M, Kornblith A, Homel P, et al. Development of a brief assessment scale for caregivers of the medically ill. J Pain Symptom Manage 2005;29:245-54.
158. Heyland DK, Cook DJ, Rocker GM, et al. Canadian Researchers at the End of Life Network. The development and validation of a novel questionnaire to measure patient and family satisfaction with end-of-life care: the Canadian Health Care Evaluation Project (CANHELP) Questionnaire. Palliat Med 2010;24:682-95.
159. Garin O, Ferrer M, Pont A, et al. Disease-specific health-related quality of life questionnaires for heart failure: a systematic review with metaanalyses. Qual Life Res 2009;18:71-85.
160. Hudson PL, Trauer T, Graham S, et al. A systematic review of instruments related to family caregivers of palliative care patients Pall Med 2010;24:656-68.
161. Steinman MA, Hanlon JT. Managing medications in clinically complex elders: "There's got to be a happy medium." JAMA 2010;304:1592-601.
162. Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002;57:939-44.
163. Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev 2010;:CD007354.
164. Eva G, Wee B. Rehabilitation in end-of-life management. Curr Opin Support Palliat Care 2010;4:158-62.
165. JL Pereira Associates. Pallium Palliative Pocketbook: A Peer-Reviewed, Referenced Resource. Edmonton, Canada: The Pallium Project, 2008.
166. SW London Cardiac Network. Available at: http://www.slcsn.nhs.uk/files/cardiac/swl-symptom-control-guidelines.pdf. Accessed on March 3, 2011.
167. National End of Life Care Programme. End of life care in heart failure: a framework for implementation. Available at: http://www.improvement.nhs.uk/LinkClick.aspx?fileticket=KBUUEsR0mms%3d&tabid=56. Accessed on March 3, 2011.
168. Walker R, Read S. The Liverpool Care Pathway in intensive care: an exploratory study of doctor and nurse perceptions. Int J Palliat Nurs 2010;16:267-73.
169. Arthur HM, Suskin N, Bayley M, et al. The Canadian Heart Health Strategy and Action Plan: cardiac rehabilitation as an exemplar of chronic disease management. Can J Cardiol 2010;26:37-41.
170. Wagner EH, Austin BT, Davis C, et al. Improving Chronic illness Care: Translating Evidence Into Action. Health Affairs 2001;20:64-78.
171. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA 2002;288:1775-9.
172. Coleman K, Austin BT, Brach C, et al. Evidence on the chronic care model in the new millennium. Health Affairs 2009; 28:75-85.
173. Hopp FP, Thornton N, Martin L. The lived experience of heart failure at the end of life: a systematic literature review. Health Soc Work 2010;25: 109-17.
174. Riegel B, Moser DK, Anker SD, et al. State of the Scinece. Promoting self-care in persons with heart failure. A scientific statement from the American Heart Association. Circulation 2009;120:1141-63.
175. Brumley R, Enguidanos S, Jamison P, et al. Increased satisfaction with care and lower costs: results of a randomized trial of in-home palliative care. JAGS 2010;55:993-1000.
176. Boehmer JP, Popjes E. Cardiac failure: mechanical support strategies. Crit Care Med 2006;34(9 suppl):S268-77.
177. Chu SH, Hsu RB. Current status of artificial hearts and ventricular assist devices. J Formos Med Assoc 2000;99:79-85.
178. Kanter KR, McBride LR, Pennington DG, et al. Bridging to cardiac transplantation with pulsatile ventricular assist devices. Ann Thorac Surg 1988;46:134-40.
179. Goldman BS, Walker P, Gunstensen J, et al. Intra-aortic balloon pump assist: adjunct to surgery for left ventricular dysfunction. Can J Surg 1976;19:128-34.
180. Aaronson KD, Patel H, Pagani FD. Patient selection for left ventricular assist device therapy. Ann Thorac Surg 2003;75(6 suppl):S29-35.
181. Mielniczuk L, Mussivand T, Davies R, et al. Patient selection for left ventricular assist devices. Artif Organs 2004;28:152-7.
182. Lietz K, Long JW, Kfoury AG, et al. Impact of center volume on outcomes of left ventricular assist device implantation as destination therapy: analysis of the Thoratec HeartMate Registry, 1998 to 2005. Circ Heart Fail 2009;2:3-10.
183. Arbustini E, Grasso M, Porcu E, et al. Healing of acute myocarditis with left ventricular assist device: morphological recovery and evolution to the aspecific features of dilated cardiomyopathy. Ital Heart J 2001;2:55-9.
184. El-Hamamsy I, White M, Pellerin M, et al. Successful explantation of a left ventricular assist device following acute fulminant myocarditis. Can J Cardiol 2006;22:507-8.
185. Farrar DJ, Holman WR, McBride LR, et al. Long-term follow-up of Thoratec ventricular assist device bridge-to-recovery patients successfully removed from support after recovery of ventricular function. J Heart Lung Transplant 2002;21:516-21.
186. Delgado DH, Ross HJ, Rao V. The dilemma of a left ventricular assist device explantation: a decision analysis. Can J Cardiol 2007;23:657-61.
187. Slaughter MS, Sobieski MA, Koenig SC, et al. Left ventricular assist device weaning: hemodynamic response and relationship to stroke volume and rate reduction protocols. ASAIO J 2006;52:228-33.
188. Chung JC, Tsai PR, Chou NK, et al. Extracorporeal membrane oxygenation bridge to adult heart transplantation. Clin Transplant 2010;24: 375-80.
189. Ko WJ, Lin CY, Chen RJ, et al. Extracorporeal membrane oxygenation support for adult postcardiotomy cardiogenic shock. Ann Thorac Surg 2002;73:538-45.
190. Pagani FD, Lynch W, Swaniker F, et al. Extracorporeal life support to left ventricular assist device bridge to heart transplant: a strategy to optimize survival and resource utilization. Circulation 1999;100(19 suppl): II-206-10.
191. Ibrahim M, Hendry P, Masters R, et al. Management of acute severe perioperative failure of cardiac allografts: a single-centre experience with a review of the literature. Can J Cardiol 2007;23:363-7.
192. Pagani FD, Aaronson KD, Swaniker F, et al. The use of extracorporeal life support in adult patients with primary cardiac failure as a bridge to implantable left ventricular assist device. Ann Thorac Surgr 2001;71: S77-81.
193. Chen JM, Levin HR, Catanese KA, et al. Use of a pulsatile right ventricular assist device and continuous arteriovenous hemodialysis in a 57-year-old man with a pulsatile left ventricular assist device. J Heart Lung Transplant 1995;14:186-91.
194. Morgan JA, John R, Lee BJ, et al. Is severe right ventricular failure in left ventricular assist device recipients a risk factor for unsuccessful bridging to transplant and post-transplant mortality. Ann Thorac Surg 2004;77: 859-63.
195. Samuels L, Holmes EC, Hagan K, et al. Incorporation of an in-line filter for ultrafiltration or hemodialysis to the Abiomed BVS5000 ventricular assist device. ASAIO J 2006;52:634-7.
196. Cheung A, Bashir J, Kaan A, et al. Minimally invasive, off-pump explant of a continuous-flow left ventricular assist device. J Heart Lung Transplant 2010;29:808-10.
197. El-Hamamsy I, Jacques F, Perrault LP, et al. Results following implantation of mechanical circulatory support systems: the Montreal Heart Institute experience. Can J Cardiol 2009;10710.
198. Russell SD, Miller LW, Pagani FD. Advanced heart failure: a call to action. Congest Heart Fail 2008;14:316-321.
199. Frazier OH, Rose EA, McCarthy P, et al. Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system. Ann Surg 1995;222:327-36.
200. Haft JW, Suzuki Y, Aaronson KD, et al. Identification of device malfunction in patients supported with the HeartMate XVE left ventricular assist system. ASAIO J 2007;53:298-303.
201. McCarthy PM, Smedira NO, Vargo RL, et al. One hundred patients with the HeartMate left ventricular assist device: evolving concepts and technology. J Thorac Cardiovasc Surg 1998;115:904-12.
202. Zierer A, Melby SJ, Voeller RK, et al. Late-onset driveline infections: the Achilles' heel of prolonged left ventricular assist device support. Ann Thorac Surg 2007;84:515-20.
203. Frazier OH, Rose EA, Macmanus Q, et al. Multicenter clinical evaluation of the HeartMate 1000 IP left ventricular assist device. Ann Thorac Surg 1992;53:1080-90.
204. Boyle AJ, Russell SD, Teuteberg JJ, et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant 2009; 28:881-7.
205. Demirozu ZT, Etheridge WB, Radovancevic R, et al. Results of Heart-Mate II left ventricular assist device implantation on renal function in patients requiring post-implant renal replacement therapy. J Heart Lung Transplant 2011;30:182-7.
206. Haft J, Armstrong W, Dyke DB, et al. Hemodynamic and exercise performance with pulsatile and continuous-flow left ventricular assist devices. Circulation 2007;116:I8-I15.
207. John R, Pagani FD, Naka Y, et al. Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables. J Thorac Cardiovasc Surg 2010;140:174-81.
208. Long JW, Kfoury AG, Slaughter MS, et al. Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study. Congest Heart Fail 2005;11: 133-8.
209. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007; 357:885-96.
210. Morgan JA, John R, Rao V, et al. Bridging to transplant with the Heart-Mate left ventricular assist device: the Columbia Presbyterian 12-year experience. J Thorac Cardiovasc Surg 2004;127:1309-16.
211. Pagani FD, Long JW, Dembitsky WP, et al. Improved mechanical reliability of the HeartMate XVE left ventricular assist system. Ann Thorac Surg 2006;82:1413-8.
212. Slaughter MS, Sobieski MA, Gallagher C, et al. Low incidence of neurologic events during long-term support with the HeartMate XVE left ventricular assist device. Tex Heart Inst J 2008;35:245-9.
213. Hendry PJ, Mussivand TV, Masters RG, et al. The HeartSaver left ventricular assist device: an update. Ann Thorac Surg 2001;71:S166-70.
214. Slaughter MS, Sobieski MA 2nd, Tamez D, et al. HeartWare miniature axial-flow ventricular assist device: design and initial feasibility test. Tex Heart Inst J 2009;36:12-6.
215. Herrmann M, Weyand M, Greshake B, et al. Left ventricular assist device infection is associated with increased mortality but is not a contraindication to transplantation. Circulation 1997;95:814-7.
216. Aaronson KD, Eppinger MJ, Dyke DB, et al. Left ventricular assist device therapy improves utilization of donor hearts. J Am Coll Cardiol 2002;39:1247-54.
217. Patlolla V, Patten RD, Denofrio D, et al. The effect of ventricular assist devices on post-transplant mortality: an analysis of the United Network for Organ Sharing thoracic registry. J Am Coll Cardiol 2009;53:264-71.
218. Carrier M, Perrault LP, Bouchard D, et al. Effect of left ventricular assist device bridging to transplantation on donor waiting time and outcomes in Canada. Can J Cardiol 2004;20:501-4.
219. Burnett CM, Duncan JM, Frazier OH, et al. Improved multiorgan function after prolonged univentricular support. Ann Thorac Surg 1993;55: 65-71.
220. Stein ML, Robbins R, Sabati AA, et al. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS)-defined morbidity and mortality associated with pediatric ventricular assist device support at a single US center: the Stanford experience. Circ Heart Fail 2010;3: 682-8.
221. Russell SD, Rogers JG, Milano CA, et al. Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. Circulation 2009;120:2352-2357.
222. Amir O, Delgado RM 3rd, Kar B, et al. Recovery from multi-organ failure in a patient with a continuous-flow left ventricular assist device. J Heart Lung Transplant 2005;24:1128-9.
223. Kirklin JK, Naftel DC, Kormos RL, et al. Second INTERMACS annual report: more than 1,000 primary left ventricular assist device implants. J Heart Lung Transplant 2010;29:1-10.
224. Feldman CM, Khan SN, Slaughter MS, et al. Improvement in early oxygen uptake kinetics with left ventricular assist device support. ASAIO J 2008;54:406-11.
225. John R, Boyle A, Pagani F, et al. Physiologic and pathologic changes in patients with continuous-flow ventricular assist devices. J Cardiovasc Transl Res 2009;2:154-158.
226. John R, Lietz K, Schuster M, et al. Immunologic sensitization in recipients of left ventricular assist devices. J Thorac Cardiovasc Surg 2003; 125:578-91.
227. Kamdar F, Boyle A, Liao K, et al. Effects of centrifugal, axial, and pulsatile left ventricular assist device support on end-organ function in heart failure patients. J Heart Lung Transplant 2009;28:352-9.
228. Pagani FD, Dyke DB, Wright S, et al. Development of anti-major histocompatibility complex class I or II antibodies following left ventricular assist device implantation: effects on subsequent allograft rejection and survival. J Heart Lung Transplant 2001;20:646-53.
229. Rogers JG, Aaronson KD, Boyle AJ, et al. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol 2010;55:1826-34.
230. Russo MJ, Hong KN, Davies RR, et al. Posttransplant survival is not diminished in heart transplant recipients bridged with implantable left ventricular assist devices. J Thorac Cardiovasc Surg 2009;138: 1425-32.
231. Slaughter MS. Outcomes of Medicare beneficiaries with ventricular assist devices. JAMA 2009;301:1657-8.
232. Vitali E, Lanfranconi M, Ribera E, et al. Successful experience in bridging patients to heart transplantation with the MicroMed DeBakey ventricular assist device. Ann Thorac Surg 2003;75:1200-4.
233. Ross H, Tinckam K, Rao V, et al. In praise of ventricular assist devicesmechanical bridge to virtual crossmatch for the sensitized patient. J Heart Lung Transplant 2010;29:728-30.
234. Cianci P, Lonergan-Thomas H, Slaughter M, et al. Current and potential applications of left ventricular assist devices. J Cardiovasc Nurs 2003; 18:17-22.
235. Daneshmand MA, Rajagopal K, Lima B, et al. Left ventricular assist device destination therapy versus extended criteria cardiac transplant. Ann Thorac Surg 2010;89:1205-9.
236. Haddad M, Lam K, Hendry P, et al. Left ventricular assist devices for the treatment of congestive heart failure. Curr Treat Options Cardiovasc Med 2005;7:47-54.
237. Lietz K, Long JW, Kfoury AG, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation 2007;116:497-505.
238. MacIver J, Ross HJ, Delgado DH, et al. Community support of patients with a left ventricular assist device: the Toronto General Hospital experience. Can J Cardiol 2009;25:e377-81.
239. Stevenson LW, Miller LW, Desvigne-Nickens P, et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Circulation 2004;110:975-81.
240. Rose EA, Moskowitz AJ, Packer M, et al. The REMATCH trial: rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure. Ann Thorac Surg 1999;67:723-30.
241. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345:1435-43.
242. Moskowitz AJ, Weinberg AD, Oz MC, et al. Quality of life with an implanted left ventricular assist device. Ann Thorac Surg 1997;64: 1764-9.
243. Slaughter MS. Long-term continuous flow left ventricular assist device support and end-organ function: prospects for destination therapy. J Card Surg 2010;25:490-4.
244. Slaughter MS, Pagani FD, Rogers JG, et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant 2010;29:S1-39.
245. Gazzoli F, Vigano M, Pagani F, et al. Initial results of clinical trial with a new left ventricular assist device (LVAD) providing synchronous pulsatile flow. Int J Artif Organs 2009;32:344-53.
246. Pagani FD. Continuous-flow rotary left ventricular assist devices with "3rd generation" design. Semin Thorac Cardiovasc Surg 2008;20: 255-63.
247. Pal JD, Klodell CT, John R, et al. Low operative mortality with implantation of a continuous-flow left ventricular assist device and impact of concurrent cardiac procedures. Circulation 2009;120:S215-9.
248. Slaughter MS, Naka Y, John R, et al. Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. J Heart Lung Transplant 2010;29:616-24.
249. Travis AR, Giridharan GA, Pantalos GM, et al. Vascular pulsatility in patients with a pulsatile- or continuous-flow ventricular assist device. J Thorac Cardiovasc Surg 2007;133:517-24.
250. Hendry PJ, Masters RG, Davies RA, et al. Mechanical circulatory support for adolescent patients: the Ottawa Heart Institute experience. Can J Cardiol 2003;19:409-12.
251. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009;361:2241-51.
252. Miller LW, Nelson KE, Bostic RR, et al. Hospital costs for left ventricular assist devices for destination therapy: lower costs for implantation in the post-REMATCH era. J Heart Lung Transplant 2006;25:778-84.
253. Russo MJ, Gelijns AC, Stevenson LW, et al. The cost of medical management in advanced heart failure during the final two years of life. J Card Fail 2008;14:651-8.
254. Alba AC, Rao V, Ivanov J, et al. Predictors of acute renal dysfunction after ventricular assist device placement. J Card Fail 2009;15:874-81.
255. Aslam S, Hernandez M, Thornby J, et al. Risk factors and outcomes of fungal ventricular-assist device infections. Clin Infect Dis 2010; 50:664-71.
256. Cowger J, Pagani FD, Haft JW, et al. The development of aortic insufficiency in left ventricular assist device-supported patients. Circ Heart Fail 2010;3:668-74.
257. Drakos SG, Janicki L, Horne BD, et al. Risk factors predictive of right ventricular failure after left ventricular assist device implantation. Am J Cardiol 2010;105:1030-5.
258. Fukamachi K, McCarthy PM, Smedira NG, et al. Preoperative risk factors for right ventricular failure after implantable left ventricular assist device insertion. Ann Thorac Surg 1999;68:2181-4.
259. Genovese EA, Dew MA, Teuteberg JJ, et al. Incidence and patterns of adverse event onset during the first 60 days after ventricular assist device implantation. Ann Thorac Surg 2009;88:1162-70.
260. Kavarana MN, Pessin-Minsley MS, Urtecho J, et al. Right ventricular dysfunction and organ failure in left ventricular assist device recipients: a continuing problem. Ann Thorac Surg 2002;73:745-50.
261. Kormos RL, Teuteberg JJ, Pagani FD, et al. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg 2010;139:1316-13.
262. Lima B, Kherani AR, Hata JA, et al. Does a pre-left ventricular assist device screening score predict long-term transplantation success? A 2-center analysis. Heart Surg Forum 2006;9:E783-5.
263. Rao V, Oz MC, Flannery MA, et al. Revised screening scale to predict survival after insertion of a left ventricular assist device. J Thorac Cardiovasc Surg 2003;125:855-62.
264. Reinhartz O, Farrar DJ, Hershon JH, et al. Importance of preoperative liver function as a predictor of survival in patients supported with Thoratec ventricular assist devices as a bridge to transplantation. J Thorac Cardiovasc Surg 1998;116:633-40.
265. Richartz BM, Radovancevic B, Frazier OH, et al. Low serum cholesterol levels predict high perioperative mortality in patients supported by a left-ventricular assist system. Cardiol 1998;89:184-8.
266. Robinson PJ, Billah B, Leder K, et al. Factors associated with deep sternal wound infection and haemorrhage following cardiac surgery in Victoria. Interact Cardiovasc Thorac Surg 2007;6:167-71.
267. Romano MA, Cowger J, Aaronson KD, et al. Diagnosis and management of right-sided heart failure in subjects supported with left ventricular assist devices. Curr Treat Options Cardiovasc Med 2010;12: 420-30.
268. Schenk S, McCarthy PM, Blackstone EH, et al. Duration of inotropic support after left ventricular assist device implantation: risk factors and impact on outcome. J Thorac Cardiovasc Surg 2006;131:447-54.
269. Topkara VK, Dang NC, Barili F, et al. Predictors and outcomes of continuous veno-venous hemodialysis use after implantation of a left ventricular assist device. J Heart Lung Transplant 2006;25:404-8.
270. Anstadt MP, Hendry PJ, Plunkett MD, et al. Mechanical myocardial actuation during ventricular fibrillation improves tolerance to ischemia compared with cardiopulmonary bypass. Circulation 1990;82(suppl): IV284-90.
271. Anderson CA, Filsoufi F, Aklog L, et al. Liberal use of delayed sternal closure for postcardiotomy hemodynamic instability. Ann Thorac Surg 2002;73:1484-8.
272. Haddad M, Hendry PJ, Masters RG, et al. Ventricular assist devices as a bridge to cardiac transplantation: the Ottawa experience. Artif Organs 2004;28:136-41.
273. Hendry PJ, Masters RG, Mussivand TV, et al. Circulatory support for cardiogenic shock due to acute myocardial infarction: a Canadian experience. Can J Cardiol 1999;15:1090-4.
274. Matthews JC, Pagani FD, Haft JW, et al. Model for end-stage liver disease score predicts left ventricular assist device operative transfusion requirements, morbidity, and mortality. Circulation 2010;121:214-20.
275. Pagani FD, Miller LW, Russell SD, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 2009;54:312-21.
276. Slaughter MS. Hematologic effects of continuous flow left ventricular assist devices. J Cardiovasc Transl Res 2010;3:618-24.
277. Slaughter MS, Tsui SS, El-Banayosy A, et al. Results of a multicenter clinical trial with the Thoratec Implantable Ventricular Assist Device. J Thorac Cardiovasc Surg 2007;133:1573-80.
278. Hendry PJ, Ascah KJ, Rajagopalan K, et al. Does septal position affect right ventricular function during left ventricular assist in an experimental porcine model? Circulation 1994;90:II353-8.
279. Matthews JC, Koelling TM, Pagani FD, et al. The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol 2008;51:2163-72.
280. Kuhne M, Sakumura M, Reich SS, et al. Simultaneous use of implantable cardioverter-defibrillators and left ventricular assist devices in patients with severe heart failure. Am J Cardiol 2010;105:378-82.
281. Malani PN, Dyke DB, Pagani FD, et al. Successful treatment of vancomycin resistant Enterococcus faecium mediastinitis associated with left ventricular assist devices. Ann Thorac Surg 2003;76:1719-20.
282. Malani PN, Dyke DB, Pagani FD, et al. Nosocomial infections in left ventricular assist device recipients. Clin Infect Dis 2002;34:1295-1300.
283. Martin SI, Wellington L, Stevenson KB, et al. Effect of body mass index and device type on infection in left ventricular assist device support beyond 30 days. Interact Cardiovasc Thorac Surg 2010;11:20-3.
284. Meyer AL, Malehsa D, Bara C, et al. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ Heart Fail 2010;3:675-81.
285. Luckraz H, Woods M, Large SR. And hemolysis goes on: ventricular assist device in combination with veno-venous hemofiltration. Ann Thorac Surg 2002;73:546-8.
286. Bagdasarian NG, Malani AN, Pagani FD, et al. Fungemia associated with left ventricular assist device support. J Card Surg 2009;24:763-5.
287. Chinn R, Dembitsky W, Eaton L, et al. Multicenter experience: prevention and management of left ventricular assist device infections. ASAIO J 2005;51:461-70.
288. Eyler RF, Butler SO, Walker PC, et al. Vancomycin use during left ventricular assist device support. Infect Control Hosp Epidemiol 2009; 30:484-6.
289. Gazzoli F, Grande AM, Pagani F, et al. Images in cardio-thoracic surgery: Novacor left ventricular assist device inflow valve endocarditis. Eur J Cardiothorac Surg 2009;35:910.
290. Grossi P, Dalla Gasperina D, Pagani F, et al. Infectious complications in patients with the Novacor left ventricular assist system. Transplant Proc 2001;33:1969-71.
291. Butany J, Leong SW, Rao V, et al. Early changes in bioprosthetic heart valves following ventricular assist device implantation. Int J Cardiol 2007;117:e20-3.
292. Feldman CM, Silver MA, Sobieski MA, et al. Management of aortic insufficiency with continuous flow left ventricular assist devices: bioprosthetic valve replacement. J Heart Lung Transplant 2006;25:1410-2.
293. Rao V, Slater JP, Edwards NM, et al. Surgical management of valvular disease in patients requiring left ventricular assist device support. Ann Thorac Surg 2001;71:1448-53.
294. Khan NA, Butany J, Zhou T, et al. Pathological findings in explanted prosthetic heart valves from ventricular assist devices. Pathology 2008;40:377-84.
295. Goldberg SG, Eckman P, Vanhaecke J. International Socieity for Heart and Lung Transplantation Google Chat page. Available at: http://groups.google.com/group/ishlt-hf/topics. Accessed January 29, 2011.